May 1 (Reuters) - Stryker beat Wall Street

estimates for quarterly profit on Thursday, fueled by strong

demand for its medical and surgical devices.

Device makers have benefited from a surge in demand as more

people in the U.S., particularly older Americans, sought health

care services and surgical procedures.

The Portage, Michigan-based company expects the demand for

surgical procedures to continue through the year-end, but

expects a tariff impact of about $200 million in 2025.

"We expect to offset tariff costs through our continued

sales momentum, the leveraging of our manufacturing footprint,

disciplined spending and better than expected foreign currency

impacts," Chief Financial Officer Preston Wells said.

Stryker revised its 2025 profit outlook to between $13.20

and $13.45 per share, down from the previous $13.45 to $13.70

range, which had excluded a 20-30 cent impact from its

acquisition of Inari Medical.

Analysts expect a profit of $13.35 per share, according to

data compiled by LSEG.

Sales at Stryker's medical surgery and neurotechnology unit

rose 13.4% to $3.5 billion, while sales at its orthopedics

segment increased 9.7% to $2.4 billion.

The company, which makes implants used in joint replacement

and trauma surgeries, said it saw some supply disruptions in the

quarter which would linger through the next quarter

Total revenue was $5.9 billion for the quarter ended March

31, above analysts' expectations of $5.7 billion.

On an adjusted basis, the company earned $2.84 per share,

beating estimates of $2.70 per share.